Phase 3 clinical studies evaluating tesamorelin in HIV-associated lipodystrophy are now completed. A New Drug Application has been submitted to the U.S. autorities and is currently under review.

Products

Click on one of the conditions below to find out more about the status of our programs.

Discovery Preclinical Phase 1 Phase 2 Phase 3 Regulatory review
Programs developed internally
HIV-associated lipodystrophy completed completed completed completed completed underway
Acute kidney Injury completed underway    
Third-party study evaluating tesamorelin
Growth hormone deficient abdominal obesity (GHDAO)* completed completed completed underway
Pre-Alzheimer syndrome (Mild cognitive impairment)** completed completed completed underway
  underway : underway   completed : completed

Our product portfolio contains therapeutic products at various stages of development aimed at answering unmet medical needs in commercially attractive markets. Our strategy is now focused on the development of our lead-product, tesamorelin, in the United States and in other potential lipodystrophy markets.

* Independent study sponsored by the National Institutes of Health and led by Dr. Grinspoon and the Massachusetts General Hospital.
** Independent study sponsored by the National Institutes of Health and led by Dr. Vitiello and the University of Washington (Seattle).